Skip to main content

Market Overview

Verona Pharma's pMDI Ensifentrine Shows Improved Lung Function In Mid-Stage COPD Study

  • Verona Pharma PLC (NASDAQ: VRNA) has reported positive data from the Phase 2 study evaluating pressurized metered-dose inhaler formulation (pMDI) of ensifentrine in moderate to severe chronic obstructive pulmonary disease. The study met all primary and secondary endpoints. 
  • Dose-ordered improvement in lung function was observed and statistically significant at peak and over the 12-hour dosing interval compared with placebo, thus supporting twice-daily dosing.
  • An increase in lung function measured by peak forced expiratory volume in one second (FEV1) were 205 mL, 277mL, and 326mL for 300 µg, 1000 µg, and 3000 µg dose, respectively.
  • Ensifentrine pMDI formulation was well tolerated at each dose with an adverse event profile similar to placebo.
  • The drug candidate is also under development in hospitalized COVID-19 patients, with results expected in Q2 this year.
  • Price Action: VRNA shares are higher by 13.4% at $8.96 in the pre-market session on the last check Tuesday.

Related Articles (VRNA)

View Comments and Join the Discussion!

Posted-In: chronic obstructive pulmonary Phase 2 Clinical TrialBiotech News Small Cap FDA Top Stories General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at